Cardioprotection in the clinical setting

Cardiovascular Drugs and Therapy

Volumn 24, Issue 3, 2010, Pages 281-287

  Ivanes, Fabrice ^a,b   Mewton, Nathan ^a,b   Rioufol, Gilles ^a,b   Piot, Christophe ^c,d   Elbaz, Meyer ^a,f   Revel, Didier ^e   Croisille, Pierre ^e   Ovize, Michel ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ LYON 1   (France)

^c INSTITUT DE GÉNOMIQUE FONCTIONNELLE   (France)

^d HÔPITAL ARNAUD DE VILLENEUVE   (France)

^e UNIVERSITÉ DE LYON   (France)

^f UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

Ischemia; Myocardial infarction; Postconditioning; Reperfusion

Indexed keywords

CREATINE KINASE; CYCLOPHILIN D; CYCLOSPORIN A; MALONALDEHYDE; MITOCHONDRIAL PERMEABILITY TRANSITION PORE;

ABSENCE OF SIDE EFFECTS; ACUTE HEART INFARCTION; BLOOD CLOT LYSIS; BLOOD FLOW VELOCITY; CLINICAL TRIAL; CORONARY ARTERY BLOOD FLOW; CORONARY STENT; CREATINE KINASE BLOOD LEVEL; DRUG MECHANISM; DRUG USE; FIBRINOLYSIS; HEART CONTRACTION; HEART INFARCTION; HEART INFARCTION PREVENTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE REMODELING; HEART LEFT VENTRICLE WALL MOTION; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEART VENTRICLE REMODELING; HUMAN; ISCHEMIC POSTCONDITIONING; NONHUMAN; OXIDATIVE STRESS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REMOTE ISCHEMIC POSTCONDITIONING; REPERFUSION; REPERFUSION INJURY; REVIEW; SINGLE DRUG DOSE; ST SEGMENT ELEVATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

ANGIOPLASTY, BALLOON, CORONARY; ANIMALS; CARDIOTONIC AGENTS; CYCLOSPORINE; HUMANS; ISCHEMIC POSTCONDITIONING; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; TIME FACTORS;

EID: 78149358999     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-010-6243-y     Document Type: Review

References (39)

1. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361:13-20.
2. Piper HM, Garcia-Dorado D, Ovize M. A fresh look at reperfusion injury. Cardiovasc Res. 1998;38:291-300.
3. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007;357:1121-35.
4. Hearse DJ, Humphrey SM, Chain EB. Abrupt reoxygenation of the anoxic potassium-arrested perfused rat heart: a study of myocardial enzyme release. J Mol Cell Cardiol. 1973;5:395-407.
5. Lemasters JJ, Bond JM, Chacon E, Harper IS, Kaplan SH, Ohata H, et al. The pH paradox in ischemia-reperfusion injury to cardiac myocytes. EXS. 1996;76:99-114.
6. Gomez L, Thibault H, Gharib A, Dumont JM, Vuagniaux G, Scalfaro P, et al. Inhibition of mitochondrial permeability transition improves functional recovery and reduces mortality following acute myocardial infarction in mice. Am J Physiol Heart Circ Physiol. 2007;293: H1654-61.
7. Penna C, Mancardi D, Raimondo S, Geuna S, Pagliaro P. The paradigm of postconditioning to protect the heart. J Cell Mol Med. 2008;12:435-58.
8. Zhao ZQ, Vinten-Johansen J. Postconditioning: reduction of reperfusion-induced injury. Cardiovasc Res. 2006;70:200-11.
9. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986;74:1124-36.
10. Otani H. Ischemic preconditioning: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal. 2008;10:207-47.
11. Crisostomo PR, Wairiuko GM, Wang M, Tsai BM, Morrell ED, Meldrum DR. Preconditioning versus postconditioning: mechanisms and therapeutic potentials. J Am Coll Surg. 2006;202:797-812.
12. Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol. 2003;285: H579-88.
13. Argaud L, Gateau-Roesch O, Raisky O, Loufouat J, Robert D, Ovize M. Postconditioning inhibits mitochondrial permeability transition. Circulation. 2005;111:194-7. (Pubitemid 40139731)
14. Dosenko VE, Nagibin VS, Tumanovskaya LV, Zagoriy VY, Moibenko AA, Vaage J. Proteasomal proteolysis in anoxiareoxygenation, preconditioning and postconditioning of isolated cardiomyocytes. Pathophysiology. 2004;62:74-85.
15. Lim SY, Davidson SM, Hausenloy DJ, Yellon DM. Preconditioning and postconditioning: the essential role of the mitochondrial permeability transition pore. Cardiovasc Res. 2007;75:530-5.
16. Piper HM, Abdallah Y, Schafer C. The first minutes of reperfusion: a window of opportunity for cardioprotection. Cardiovasc Res. 2004;61:365-71.
17. Staat P, Rioufol G, Piot C, Cottin Y, Cung TT, L'Huillier I, et al. Postconditioning the human heart. Circulation. 2005;112:2143-8.
18. Reimer KA, Jennings RB. The "wavefront phenomenon" of myocardial ischemic cell death. II. Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. Lab Invest. 1979;40:633-44.
19. Thibault H, Piot C, Staat P, Bontemps L, Sportouch C, Rioufol G, et al. Long-term benefit of postconditioning. Circulation. 2008;117:1037-44.
20. Laskey WK. Brief repetitive balloon occlusions enhance reperfusion during percutaneous coronary intervention for acute myocardial infarction: a pilot study. Catheter Cardiovasc Interv. 2005;65:361-7.
21. Laskey WK, Yoon S, Calzada N, Ricciardi MJ. Concordant improvements in coronary flow reserve and ST-segment resolution during percutaneous coronary intervention for acute myocardial infarction: a benefit of postconditioning. Catheter Cardiovasc Interv. 2008;72:212-20.
22. Ma X, Zhang X, Li C, Luo M. Effect of postconditioning on coronary blood flow velocity and endothelial function and LV recovery after myocardial infarction. J Interv Cardiol. 2006;19:367-75. (Pubitemid 44511065)
23. Sun HY, Wang NP, Kerendi F, Halkos M, Kin H, Guyton RA, et al. Hypoxic postconditioning reduces cardiomyocyte loss by inhibiting ROS generation and intracellular Ca2+ overload. Am J Physiol Heart Circ Physiol. 2005;288: H1900-8.
24. Hausenloy DJ, Ong SB, Yellon DM. The mitochondrial permeability transition pore as a target for preconditioning and postconditioning. Basic Res Cardiol. 2009;104:189-202.
25. Baines CP, Kaiser RA, Purcell NH, Blair NS, Osinska H, Hambleton MA, et al. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature. 2005;434:658-62.
26. Basso E, Fante L, Fowlkes J, Petronilli V, Forte MA, Bernardi P. Properties of the permeability transition pore in mitochondria devoid of Cyclophilin D. J Biol Chem. 2005;280:18558-61.
27. Nakagawa T, Shimizu S, Watanabe T, Yamaguchi O, Otsu K, Yamagata H, et al. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature. 2005;434:652-8.
28. Argaud L, Gateau-Roesch O, Muntean D, Chalabreysse L, Loufouat J, Robert D, et al. Specific inhibition of the mitochondrial permeability transition prevents lethal reperfusion injury. J Mol Cell Cardiol. 1988;255:357-60.
29. Halestrap AP, Davidson AM. Inhibition of Ca2 (+)-induced largeamplitude swelling of liver and heart mitochondria by cyclosporin is probably caused by the inhibitor binding to mitochondrialmatrix peptidyl-prolyl cis-trans isomerase and preventing it interacting with the adenine nucleotide translocase. Biochem J. 1990;268:153-60.
30. Tanveer A, Virji S, Andreeva L, Totty NF, Hsuan JJ, Ward JM, et al. Involvement of cyclophilin D in the activation of a mitochondrial pore by Ca2+ and oxidant stress. Eur J Biochem. 1996;238:166-72.
31. Woodfield K, Ruck A, Brdiczka D, Halestrap AP. Direct demonstration of a specific interaction between cyclophilin-D and the adenine nucleotide translocase confirms their role in the mitochondrial permeability transition. Biochem J. 1998;336(Pt 2):287-90.
32. Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med. 2008;359:473-81.
33. Mewton N, Croisille P, Gahide G, Rioufol G, Bonnefoy E, Sanchez I, et al. Effect of cyclosporine on left ventricular remodeling after reperfused myocardial infarction. J Am Coll Cardiol. 2010;55:1200-5.
34. Fiedler B, Wollert KC. Interference of antihypertrophic molecules and signaling pathways with the Ca2+-calcineurin-NFAT cascade in cardiac myocytes. Cardiovasc Res. 2004;63:450-7.
35. Kerendi F, Kin H, Halkos ME, Jiang R, Zatta AJ, Zhao ZQ, et al. Remote postconditioning. Brief renal ischemia and reperfusion applied before coronary artery reperfusion reduces myocardial infarct size via endogenous activation of adenosine receptors. Basic Res Cardiol. 2005;100:404-12.
36. Botker HE, Kharbanda R, Schmidt MR, Bottcher M, Kaltoft AK. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet. 2010;375:727-34.
37. Ovize M, Bonnefoy E. Giving the ischaemic heart a shot in the arm. Lancet. 2010;375:699-700.
38. Downey JM, Cohen MV. Why do we still not have cardioprotective drugs? Circ J. 2009;73:1171-7.
39. Aletras AH, Tilak GS, Natanzon A, Hsu LY, Gonzalez FM, Hoyt Jr RF, et al. Retrospective determination of the area at risk for reperfused acute myocardial infarction with T2-weighted cardiac magnetic resonance imaging: histopathological and displacement encoding with stimulated echoes (DENSE) functional validations. Circulation. 2006;113:1865-70.